


- Medlem af instruksudvalg for obstetrik i Region Midtjylland.
- Medlem af perinatal audit/vest-gruppen i Region Midtjylland.



## Fertilitetsklinikken

### Præsentation af afdelingens vigtigste forskningsaktivitet

I 2018 forsvarede vores første Ph.d. sin afhandling i august. Opponentterne fra Australien og England var meget tilfredse og imponerede. En stor og festlig dag for alle.

Året har været præget af stor aktivitet og stort fokus på forskningen.

Klinikken har været involveret i mange projekter, de fleste forskerinitierede, men også projekter initieret af industrien. Vi har fået tilknyttet flere yngre forskere, der er godt i gang med forskellige opgaver og forsknings projekter. En af vores yngre forskere har fået tildelt Lundbeckfondens talentpris – meget fornemt.

Der er mange projekter i gang og alle gør en kæmpestor indsats og bidrager til deres gennem-førelse.

Der har været stor deltagelse fra forskellige fag-grupper i faglige kongresser såvel nationalt som internationalt. Ligeledes har afdelingen selv været vært for internationale faglige møder.

Afdelingen arbejder fortsat på at blive Universitetsklinik. Man har fra regionens side ønsket at få én fælles Universitetsklinik. Arbejdet fortsætter derfor i samarbejde med Fertilitetsklinikken i Horsens.

### Klinikchef

Overlæge Helle Olesen Elbæk

### Forskningsansvarlig

Professor dr.med. Peter Humaidan

Tlf.: 78445773

E-mail: peter.humaidan@midt.rm.dk

### Ansatte med dr.med.-grad

Humaidan P, professor, dr.med. (Aarhus Universitet).

### Ansatte med ph.d.-grad

Esteves S, adjungeret professor, ph.d. (Aarhus Universitet).

Laursen RJ, afdelingslæge, ph.d.

Polyzos N, adjungeret professor, ph.d. (Aarhus Universitet).

### Ansatte med anden videnskabelig grad

Mikkelsen AT, study nurse, m.sc. klinisk sygepleje.

Povlsen BB, laboratorieleder, m.sc. embryology.

Jensen MB, cand. scient. med.

### Lektorer

Alsbjerg B, ekstern lektor, Aarhus Universitet.

### Ph.d.-studerende

Louise Svenstrup

Assisteret reproduktion og den tidlige luteal fase – ovulationsinduktionens påvirkning af den endo-krine profil.

Syddansk Universitet, Odense.

Hovedvejleder: Peter Humaidan.

Thor Haahr

The microbiome of infertile couples and its effect on their reproductive outcome.

Aarhus Universitet.

Hovedvejleder: Peter Humaidan.

Medvejledere: Jørgen Skov Jensen, Niels Ulbjerg.

## Ph.d.-afhandling

Lise Haaber Thomsen

The impact of luteal serum progesterone levels on reproductive outcomes following IVF treatment and fresh embryo transfer : PhD dissertation. Aarhus: Health, Aarhus University; 2018.

## Igangværende forskningsprojekter

### Forsker-initierede projekter

- A double-blind, placebo-controlled multicenter trial on the effect of clindamycin and probiotic on the reproductive outcomes of IVF patients with abnormal vaginal microbiota.  
**Haahr T**, supervised by **Humaidan P**.
- A multicentre randomized trial of a "Freeze all and transfer later" versus conventional "Fresh embryo transfer" strategy for assisted reproductive technology (ART) in women with a regular cycle.  
Pinborg A, **Humaidan P**.
- Daytime profile salivary progesterone during the mid-luteal phase of IVF and FET cycles.  
Alsbjerg B.
- Substitueret fryseprotokol med GnRH-agonist, der er kontrolleret, randomiseret multicenter-studie med flere danske klinikker involveret.  
Alsbjerg B.
- Testosterone TRANSdermal gel for poor ovarian responders trial.  
**Polyzos N, Humaidan P**.
- The exogenous progesterone free luteal phase after GnRHa trigger – a randomized controlled pilot study in high-responder IVF patients.  
Humaidan P.
- The exogenous progesterone free luteal phase after GnRHa trigger – a randomized controlled pilot study in normo-responder IVF patients.  
Humaidan P.
- The microbiome of infertile couples and its effect on the reproductive outcomes – a prospective cohort study.  
**Haahr T**, supervised by **Humaidan P**.

### Medicinalindustri-initierede projekter.

- A phase IV, single-blinded, prospective, randomized, controlled, multicenter, study to compare clinical outcomes of GERI + timelapse system with conventional embryo culture and assessment system.  
Povlsen BB.
- Implant 2 – et fase 3 dobbeltblinded, randomiseret, placebo-kontrolleret studie med det formål at undersøge sikkerheds effekten af

en enkelt dosis oralt nolasiban til forbedring af graviditetsfrekvensen i IVF /ICSI med oplægning på dag 3 eller 5.

**Humaidan P, Elbaek H.**

## Publikationer

### Artikler – Peer reviewed

- 1) Abbara A, Islam R, Clarke SA, Jeffers L, Christopoulos G, Comninou AN, Salim R, Lavery SA, Vuong TNL, **Humaidan P**, Kelsey TW, Trew GH, Dhillo WS.  
Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment. Clin Endocrinol (Oxf) 2018 Jun;88(6):920-927.
- 2) Abbara A, Vuong LN, Ho VNA, Clarke SA, Jeffers L, Comninou AN, Salim R, Ho TM, Kelsey TW, Trew GH, **Humaidan P**, Dhillo WS. Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte. Front Endocrinol (Lausanne) 2018 Apr 25; 9:193.
- 3) Aflatoonian A, Mansoori-Torshizi M, Farid Mojtahedi M, Aflatoonian B, Khalili MA, Amir-Arjmand MH, Soleimani M, Aflatoonian N, Oskouian H, Tabibnejad N, **Humaidan P**. Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study. Int J Reprod Biomed (Yazd) 2018 Jan; 16(1):9-18.
- 4) **Alsbjerg B, Thomsen L, Elbaek HO, Laursen R, Povlsen BB, Haahr T, Humaidan P**. Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes. Reprod Biomed Online 2018 Nov;37(5): 641-647.
- 5) Bosch E, Bulletti C, Copperman AB, Fanchin R, Yarali H, Petta CA, Polyzos NP, Shapiro D, Ubaldi FM, Garcia Velasco JA, Longobardi S, D'Hooghe T, **Humaidan P**, Delphi TTP Consensus Group. How time to healthy single-ton delivery could affect decision-making during infertility treatment: a Delphi consensus. Reprod Biomed Online 2018 Nov 7;[Epub ahead of print].

- 6) Drakopoulos P, Rosetti J, Pluchino N, Blockeel C, Santos-Ribeiro S, de Brucker M, Drakakis P, Camus M, Tournaye H, **Polyzos NP**. Does the type of GnRH analogue used, affect live birth rates in women with endometriosis undergoing IVF/ICSI treatment, according to the rAFS stage? *Gynecol Endocrinol* 2018 Oct;34(10):884-889.
- 7) **Esteves SC**, Carvalho JF, Martinhago CD, Melo AA, Bento FC, **Humaidan P**, Alviggi C, POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) Group. Estimation of age-dependent decrease in blas-tocyst euploidy by next generation sequen-cing: development of a novel prediction model. *Panminerva Med* 2018 Jun 28;[Epub ahead of print].
- 8) Grode L, Bech BH, Plana-Ripoll O, Bliddal M, Agerholm IE, **Humaidan P**, Ramlau-Hansen CH. Reproductive life in women with celiac disease, a nationwide, population-based matched cohort study. *Hum Reprod* 2018 Jun 15;[Epub ahead of print].
- 9) Grode LB, Agerholm IE, **Humaidan P**, Parkner T, Bech BH, Ramlau-Hansen CH, Jensen TM. Unrecognised coeliac disease among men and women undergoing fertility treatment: A screening study. *United European Gastroenterol J* 2018 Dec; 6(10):1477-1484.
- 10) Gustafson LW, Christiansen AG, Majeed H, **Humaidan P**. Nonspecific Symptoms in a Rare Case of Urethral Adenocarcinoma in a 58-Year-Old Female. *Case Rep Obstet Gynecol* 2018 May 23;2018:9010246.
- 11) **Haahr T, Humaidan P, Elbaek HO, Alsbjerg B, Laursen RJ**, Rygaard K, Johannesen TB, Andersen PS, Ng KL, Jensen JS. Vaginal microbiota and IVF outcomes: development of a simple diagnostic tool to predict patients at risk of a poor reproductive outcome. *J Infect Dis* 2018 Dec 29;[Epub ahead of print].
- 12) **Haahr T**, Zacho J, Brauner M, Shathmigha K, Skov Jensen J, **Humaidan P**. Reproductive outcome of patients undergoing in vitro fertilization treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. *BJOG* 2018 Feb 22;[Epub ahead of print].
- 13) Ketheeswaran S, **Haahr T, Povlsen B, Laursen R, Alsbjerg B, Elbaek H, Esteves SC, Humaidan P**. Protein supplementation intake for bodybuilding and resistance training may impact sperm quality of subfertile men undergoing fertility treatment: a pilot study. *Asian J Androl* 2018 Sep 18;[Epub ahead of print].
- 14) Kristensen SG, **Humaidan P**, Coetzee K. Mitochondria and reproduction: possibilities for testing and treatment. *Panminerva Med* 2018 Jun 28;[Epub ahead of print].
- 15) **Laursen RJ, Alsbjerg B**, Vogel I, Gravholt CH, **Elbaek H**, Lildballe DL, **Humaidan P**, Vestergaard EM. Case of successful IVF treatment of an oligo-spermic male with 46,XX/46,XY chimerism. *J Assist Reprod Genet* 2018 Jul;35(7):1325-1328.
- 16) Lehert P, Chin W, Schertz J, D'Hooghe T, Alviggi C, **Humaidan P**. Predicting live birth for poor ovarian responders: the PROsPeR concept. *Reprod Biomed Online* 2018 Jul;37(1):43-52.
- 17) Ozgur K, Bulut H, Berkkanoglu M, **Humaidan P**, Coetzee K. Artificial cryopreserved embryo transfer cycle success depends on blastocyst developmental rate and progesterone timing. *Reprod Biomed Online* 2018 Mar;36(3):269-276.
- 18) Roque M, **Haahr T**, Geber S, **Esteves SC, Humaidan P**. Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. *Hum Reprod Update* 2018 Nov 2;[Epub ahead of print].
- 19) Roque M, Nuto Nobrega B, Valle M, Sampaio M, Geber S, **Haahr T, Humaidan P, Esteves SC**. Freeze-all strategy in IVF/ICSI cycles: an

update on clinical utility.  
Panminerva Med 2018 Jun 28;[Epub ahead of print].

- 20) **Thomsen LH, Humaidan P**, Erb K, Overgaard M, Andersen CY, Kesmodel US. Mid-Luteal 17-OH Progesterone Levels in 614 Women Undergoing IVF-Treatment and Fresh Embryo Transfer-Daytime Variation and Impact on Live Birth Rates. *Front Endocrinol (Lausanne)* 2018 Nov 29; 9:690.
- 21) **Thomsen LH**, Kesmodel US, Andersen CY, **Humaidan P**. Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment. *Front Endocrinol (Lausanne)* 2018 Mar 19; 9:92.
- 22) **Thomsen LH**, Kesmodel US, Erb K, Bungum L, Pedersen D, Hauge B, **Elbaek HO, Povlsen BB**, Andersen CY, **Humaidan P**. The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles. *Hum Reprod* 2018 Jun 28;[Epub ahead of print].  
Reply: *Hum Reprod* 2018 Dec 1;33(12):2314-2315.

#### Artikler - Review

- 1) Alviggi C, Conforti A, **Esteves SC**, Andersen CY, Bosch E, Buhler K, Ferraretti AP, De Placido G, Mollo A, Fischer R, **Humaidan P**, International Collaborative Group for the Study of r-hLH (iCOS-LH). Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. *Fertil Steril* 2018 Apr;109(4):644-664.
- 2) Alviggi C, Conforti A, Santi D, **Esteves SC**, Andersen CY, **Humaidan P**, Chiodini P, De Placido G, Simoni M. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. *Hum Reprod Update* 2018 Sep 1;24(5):599-614.
- 3) **Esteves SC**, Roque M, Bedoschi G, **Haahr T, Humaidan P**. Intracytoplasmic sperm injection for male infertility and consequences for offspring. *Nat Rev Urol* 2018 Sep;15(9):535-562.
- 4) **Esteves SC**, Roque M, Bedoschi GM, Conforti A, **Humaidan P**, Alviggi C.

Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why. *Front Endocrinol (Lausanne)* 2018 Aug 17; 9:461.

- 5) **Haahr T, Esteves SC, Humaidan P**. Individualized controlled ovarian stimulation in expected poor-responders: an update. *Reprod Biol Endocrinol* 2018 Mar 9;16(1):20-018-0342-1.

#### Editorial

- 1) **Humaidan P**, Kristensen SG, Coetzee K. Mitochondrial DNA, a new biomarker of embryonic implantation potential: fact or fiction? *Fertil Steril* 2018 Jan;109(1):61-62.

#### Letter

- 1) **Haahr T, Esteves SC, Humaidan P**. Poor definition of poor-ovarian response results in misleading clinical recommendations. *Hum Reprod* 2018 May 1;33(5):979-980.
- 2) La Marca A, Blockeel C, Bosch E, Fanchin R, Fatemi HM, Fauser BC, Garcia-Velasco JA, **Humaidan P**, Tarlatzis BC, Nelson SM. Individualized FSH dosing improves safety and reduces iatrogenic poor response while maintaining live-birth rates. *Hum Reprod* 2018 May 1;33(5):982-983.  
Corrigendum: *Hum Reprod* 2018 Jul 1; 33(7): 1372.
- 3) Roque M, **Haahr T, Esteves SC, Humaidan P**. The 'Big Freeze': freeze-all should not be used for everyone. *Hum Reprod* 2018 Jun 15;[Epub ahead of print].

#### Publiceret abstract

- 1) **Alsbjerg B, Hahr T, Elbaek HO, Laursen R, Povlsen BB, Humaidan P**. The Bologna criteria patient and dual stimulation for IVF using long-acting FSH - a cohort study. *Human Reproduction* 2018 JUL;33:440-441.
- 2) Andersen MF, Drakopoulos P, Humaidan P, Gomez JL, Bruna I, Rombauts L, Ribeiro SDS, Dosouto C, Coroleu B, Barri PN, **Polyzos NP**. Off-label use of androgens and letrozole in infertile women - a multinational survey in Europe and Australia. *Human Reproduction* 2018 JUL;33:499-499.

- 3) **Esteves S**, Carvalho JF, Martinhago C, Dias AM, **Humaidan P**, Alviggi C, Conforti A, Ubaldi F, Fischer R, Buehler K, Andersen CY. A novel maternal age and blastocyst cohort size-based prediction model estimating the probability of obtaining at least one euploid blastocyst for transfer in IVF/ICSI cycles. Human Reproduction 2018 JUL;33:321-322.
- 4) **Esteves S, Humaidan P**, Carvalho J, Ciro M, Dias A, Alviggi C, Conforti A, Fischer R, Andersen C, Buhler K, Ubaldi F. Estimation of age-dependent decrease in blastocyst euploidy in in vitro fertilization/ intracytoplasmic sperm injection cycles. Human Reproduction 2018 JUL;33:4-4.
- 5) **Haahr T**, Kesmodel US, Andersen CY, **Thomsen LH, Humaidan P**. Daytime variation in serum progesterone during the mid-luteal phase in women undergoing IVF treatment. Human Reproduction 2018 JUL;33:109-109.
- 6) **Thomsen L**, Kesmodel US, Erb K, **Humaidan P**. Mid-luteal serum progesterone levels determine the reproductive outcome following controlled ovarian stimulation. A prospective study of 602 IVF/ICSI cycles. Human Reproduction 2018 JUL;33:345-346.

### Kongresbidrag

Alsbjerg B.

Luteal phase support in frozen embryo transfer (FET).

Art success – the why, the when and the how. København, september 2018. (Invited speaker).

Alsbjerg B.

Progesterone levels on pregnancy test day after HRT – cryopresented embryo transfer cycles and related reproductive outcomes.

Evidence Based Assisted Reproduction Tecnology. Barcelona, Spanien, april 2018. (Invited speaker).

Haahr T.

The importance of the microbiome for ART outcomes - therapeutic possibilities. Nordic Fertility Innovation. november 2018. (Invited speaker).

Haahr T.

Microbiome of the female reproductive tract. NILS 18th Annual meeting. Oslo, Norge, september 2018. (Invited speaker).

Haahr T.

Den tunge administrative byrde på forskerne.

Nationale Videnskabsetiske Komites årsmøde 2018. København, maj 2018. (Invited speaker).

Humaidan P.

Advances in controlled ovarian stimulation. Portuguese IVF specialist meeting. Lissabon, Portugal, oktober 2018. (Invited speaker).

Humaidan P.

Advances in controlled ovarian stimulation. Portuguese IVF specialist meeting. Porto, Portugal, oktober 2018. (Invited speaker).

Humaidan P.

ART cycles tailored for POR patients. Azadi Hotel Conference centre. Teheran, Iran, februar 2018. (Invited speaker).

Humaidan P.

ART success- the why, the when, the how. Danish Fertility Meeting, sponsored by Gedeon Richter. København, september 2018. (Chairman/moderator).

Humaidan P.

Can we optimise the reproductive outcomes of fresh and frozen embryo transfer? ESHRE – Gedeon Richter Symposium. Barcelona, Spanien, juli 2018. (Invited speaker).

Humaidan P.

Choosing the best protocol for IVF. Obstetric and Gynaecological society of Thessaloniki. Second Congress. Thessaloniki, Grækenland, september 2018. (Chairman/moderator).

Humaidan P.

Controlling critical details to maximize success in ART – The clinical perspective 360 degrees in ART. Dexeus Forum. Madrid, Spain, november 2018. (Invited speaker).

Humaidan P.

DUOStim: from physiology to practice - Why, how, and for whom. New challenges in ovarian stimulation. East Danish IVF doctors annual meeting. København, oktober 2018. (Invited speaker).

Humaidan P.

Endocrine differences between the GnRH antagonist and GnRH agonist protocols. New concepts of reproductive Endocrinology and Infertility, Sun Yat-Sen University. Guangzhou, Kina, marts 2018. (Invited speaker).

Humaidan P.

Follicular and luteal phase. 350 Years of Merck curiosity. Kuala Lumpur, Malaysia, november 2018. (Masterclass).

Humaidan P.  
 Fresh transfer of best embryos.  
 Obstetric and Gynaecological Society of  
 Thessaloniki – Second Congress. Thessaloniki,  
 Grækenland, september 2018. (Invited  
 speaker).

Humaidan P.  
 From POR to low prognosis.  
 Fertility expert forum. Guangzhou, Kina, marts  
 2019. (Invited speaker).

Humaidan P.  
 From POR to low prognosis – new POSEIDON  
 stratification.  
 Fertility Expert Workshop. Wuhan, Kina, marts  
 2018. (Invited speaker).

Humaidan P.  
 From POR to low prognosis – new POSEIDON  
 stratification.  
 Wuhan University Peoples Hospital. Wuhan,  
 Kina, marts 2018. (Invited speaker).

Humaidan P.  
 From POR to low prognosis – new POSEIDON  
 stratification.  
 Hubei Maternal and Child Health Hospital.  
 Wuhan, Kina, marts 2018. (Invited speaker).

Humaidan P.  
 From POR to low prognosis – new POSEIDON  
 stratification.  
 Union Hospital, Tongji Medical College,  
 Huazhong University. Wuhan, Kina, marts 2018.  
 (Invited speaker).

Humaidan P.  
 From POR to low prognosis – new POSEIDON  
 stratification.  
 Tongji Hospital, affiliated to Huazhong  
 University. Wuhan, Kina, marts 2018. (Invited  
 speaker).

Humaidan P.  
 From POR to low prognosis – The new  
 POSEIDON criteria.  
 Saudi Fertility Group 7th Annual Meeting.  
 Bahrain, december 2018. (Invited speaker).


Humaidan P.  
 GnRHa trigger – State of the ART.  
 Saudi Fertility Group 7th Annual Meeting.  
 Bahrain, december 2018. (Invited speaker).

Humaidan P.  
 GnRHa trigger – State of the ART.  
 Luteal phase expert meeting. Frankfurt,  
 Tyskland, januar2018. (Invited speaker).

Humaidan P.  
 GnRHa trigger and fresh transfer – state of the  
 ART.  
 44th International DEXEUS Forum. Barcelona,  
 Spain, november 2018. (Invited speaker).

Humaidan P.  
 ICOS in poor responders – An Update.  
 4th Sincere ART Workshop. Singapore,  
 november 2018. (Invited speaker).

Humaidan P.  
 Impact on age on treatment options.



Novel strategies to predict and optimize outcomes in ART. Lissabon, Portugal, april 2018. (Chairman/moderator).

Humaidan P.  
Implantation failure, mechanisms and predictive factors.  
Reproductive biology – from genesis to baby, ReproUnion PhD course. København, februar 2018. (Invited speaker).

Humaidan P.  
Individualized controlled ovarian stimulation iCOS. Fertility expert meeting. Haifa, Israel, juni 2018. (Invited speaker).

Humaidan P.  
Individualized controlled ovarian stimulation iCOS. Fertility expert meeting. Tel Aviv, Israel, juni 2018. (Invited speaker).

Humaidan P.  
Lessons learned for modified luteal phase support after GnRHa trigger.  
ESHRE SIG endocrinology course on luteal phase. Hamborg, Tyskland, maj 2018. (Invited speaker).

Humaidan P.  
LH supplementation and use of the GnRH antagonist protocol.  
Guangzhou Workshop. Guangzhou, Kina, november 2018. (Masterclass).

Humaidan P.  
Links between the microbiome and human reproduction.  
4th Sincere ART Workshop. Singapore, november 2018. (Invited speaker).

Humaidan P.  
Links between the microbiome and human reproduction.  
Narture International Summit on Reproductive Medicine. Lugano, Schweiz, September 2018. (Invited speaker).

Humaidan P.  
Luteal phase and luteal phase support.  
Meet the expert session, Theramex. Madrid, Spanien, november 2018. (Masterclass).

Humaidan P.  
Management of poor responder patients.  
Focus group Meeting for Fertility. Beirut, Libanon, februar 2018. (Chairman/moderator).

Humaidan P.  
Management of POR in IVF: is there anything new?  
New updates in ART workshop. Abu Dhabi, Forenede Arabiske Emirater, april 2018. (Invited speaker).

Humaidan P.  
Management of Poseidon Groups 3 and 4.  
Avecina IVF Centre. Teheran, iran, februar 2018. (Invited speaker).

Humaidan P.  
Management of Poseidon Groups 3 and 4.  
Sareem Hospital. februar 2018. (Invited speaker).

Humaidan P.  
Matching patients and protocols in low prognosis – is it possible?  
PUTH memorial Forum. Beijing, Kina, marts 2018. (Invited speaker).

Humaidan P.  
New strategy for trigger – GnRHa and Kisspeptin. New concepts of reproductive Endocrinology and Infertility, Sun Yat-Sen University. Guangzhou, Kina, marts 2018. (Invited speaker).

Humaidan P.  
Nordic Fertility Innovation. Stockholm, Sverige, november 2018. (Scientific organizer/co-organizer).

Humaidan P.  
Nordic Fertility Innovation. Stochholm, Sverige, november 2018. (Chairman/moderator).

Humaidan P.  
Novel technologies in assessment of endometrial, sperm, and oocyte quality.  
Novel strategies to predict and optimize outcomes in ART. Lissabon, Portugal, april 2018. (Chairman/moderator).

Humaidan P.  
Ovarian stimulation strategies – maximizing efficiency in ART to reduce time to live birth.  
350 years of MERCK curiosity in ART 2018.  
Kuala Lumpur, Malaysia, november 2018. (Invited speaker).

Humaidan P.  
Personalized luteal phase support – The future of ART?  
The Israeli Fertility Association. Tel Aviv, Israel, juni 2018. (Invited speaker).

Humaidan P.  
Perspectives and therapeutic strategies according to the Poseidon groups.  
Nouveau Concept de Individualisation des Patients de Mauvais Prognostic. Paris, Frankrig, maj 2018. (Invited speaker).

Humaidan P.  
POR prognosis patients: Poseidon subgroups and management.

2nd DTOGI Conference. Teheran, Iran, februar 2018. (Invited speaker).

Humaidan P.  
POR prognosis patients: Poseidon subgroups and management.  
Reproductive specialist meeting. Amman, Jordan, februar 2018. (Invited speaker).

Humaidan P.  
The POSEIDON Classification - Therapeutic strategies and management.  
Austrian Reproductive Society. Innsbruck, Østrig, oktober 2018. (Invited speaker).

Humaidan P.  
The POSEIDON Classification - Therapeutic strategies and management.  
Shaare Zedek medical Center. Jerusalem, Israel, juni 2018. (Invited speaker).

Humaidan P.  
The POSEIDON Classification - Therapeutic strategies and management.  
Hadassah Hospital. Jerusalem, Israel, juni 2018. (Invited speaker).

Humaidan P.  
The POSEIDON Classification - Therapeutic strategies and management.  
Rabin Medical Center. Tel Aviv, Israel, juni 2018. (Invited speaker).

Humaidan P.  
The POSEIDON Classification - Therapeutic strategies and management. Tel Aviv Sourasky Medical center. Tel Aviv, Israel, juni 2018. (Invited speaker).

Humaidan P.  
POSEIDON classification – therapeutic strategies and management.  
Chinese Society for Reproductive Medicine (CSRМ). Chongqing, Kina, november 2018. (Invited speaker).

Humaidan P.  
Prevention of severe OHSS: Agonist trigger and individualized luteal support.  
SEHA Reproductive medicine/IVF conference. Abu Dhabi, Forenede Arabiske Emirater, april 2018. (Invited speaker).

Humaidan P. Progesterone support in ART.  
Saudi Fertility Group 7th Annual Meeting. Bahrain, december 2018. (Invited speaker).

Humaidan P.  
Repro-battle: To freeze or not to freeze. Don't freeze all.  
4th ReproYoung Conference. Ystad, Sverige, oktober 2018. (Invited speaker).

Humaidan P.  
Research and bureaucracy. The National Scientific Ethical Board Yearly Meeting. København, maj 2018. (Invited speaker).

Humaidan P.  
Stimulation of IVF patients after ovarian cryopreservation.  
The Copenhagen workshop on cryopreservation of ovarian tissue, Rigshospitalet. København, januar 2018. (Invited speaker).

Humaidan P.  
Stimulation of patients after ovarian tissue cryopreservation.  
Ovarian cryopreservation workshop, Rigshospitalet. København, april 2018. (Invited speaker).

Humaidan P.  
Urinary versus rec FSH, LH, and HCG.  
The first Hospital affiliated to AMU. Chongqing, Kina, november 2018. (Masterclass).

Humaidan P.  
Urinary versus rec FSH, LH, and HCG.  
Clinical experience sharing in COS, The second affiliated hospital of Chongqing. Chongqing, Kina, november 2018. (Masterclass).

Humaidan P.  
Use of rLH for COS and implementation of the GnRH antagonist protocol. Southern Medical University Nanfang. Guangzhou, Kina, november 2018. (Masterclass).

Humaidan P.  
The use of the ART calculator for low prognosis patients.  
PUTH memorial Forum. Beijing, Kina, marts 2018. (Invited speaker).

Humaidan P.  
Uterine receptivity and recurrent implantation failure.  
New updates in ART workshop. Abu Dhabi, Forenede Arabiske Emirater, april 2018. (Invited speaker).

Humaidan P.  
What is the Poseidon classification?  
Nouveau Concept de Individualisation des Patients de Mauvais Prognostic. Paris, Frankrig, maj 2018. (Invited speaker).

Humaidan P.  
Why should we be critically minded about Meta-analysis in ART?  
2nd DTOGI Conference. Teheran, Iran, februar 2018. (Invited speaker).



Kumarasamy SK.  
Does protein supply taken in relation to workout impact sperm quality?  
4th ReproYoung Conference. Ystad, Sverige, oktober 2018. (Oral præsentation).

Povlsen BB.  
Nordic IVF Laboratory Society Meeting. Oslo, Norge, september 2018. (Chairman).

## Undervisning

Birgit Alsbjerg

- Ekstern lektor, Aarhus Universitet.

Peter Humaidan

- Professor, AUH.

Shatmiga Ketheeswaran Kumarasamy

- Undervist i reproduktion, Det Rullende Universitet.

Thor Haahr

- Klinisk assistent, AUH og Hospitalsenhed Midt.
- Gynækologiske infektioner, Aarhus Universitet.
- Vejleder for 2 kandidatspecialer, MD, Aarhus Universitet.

## Udvalgsarbejde og anden virksomhed

Bettina B. Povlsen

- Bestyrelsesmedlem, Dansk Fertilitetsselskab (DFS).
- Formand, Nordic IVF-Laboratory Society (NILS).

Birgit Alsbjerg.

- Guideline udarbejdelse. Dansk Fertilitetsselskab.

Helle Elbæk

- Medlem af regional gruppe af fertilitetslæger, der bl.a. udarbejder regional forløbsbeskrivelse til praksis.dk.
- Medlem af subspecialiseringsudvalg med henblik på at forbedre subspecialiseringsuddannelsen i infertilitet af speciallæger i gynækologi/obstetrik.

Lise Thomsen

- Censor ved medicinsk kandidateksamen i gyn/obs, Aarhus Universitet.

Peter Humaidan

- Vejledning for bachelorprojekt, Aarhus Universitet.
- Vejleder for 5 masterprojekter, Aarhus Universitet.

Rita Laursen

- Censor ved medicinsk kandidateksamen i gyn/obs, Aarhus Universitet.

Thor Haahr

- Guideline udarbejdelse (vaginal seeding). Dansk Selskab for Gynækologi og Obstetrik.
- Vejleder for kandidat- og bachelorprojekt, Aarhus Universitet.

## Videnskabelig bedømmelse

Birgit Alsbjerg

- Reviewer for European Journal of Obstetrics & Gynecology and Reproductive Biology, Frontiers, Human Reproduction og Reproductive Biomedicine Online.

Helle Elbæk

- Reviewer for Ugeskrift for Læger.

Lise Thomsen

- Reviewer for Asian Journal of Andrology, Human Fertility, Medicine og PLoS One.

Peter Humaidan

- Associate editor: Frontiers in Endocrinology
- Reviewer for Acta Obstetrica et Gynecologica Scandinavica, Archives of Gynecology and Obstetrics, Asian Journal of Andrology, Fertility and Sterility, Gynecological Endocrinology, Human Reproduction, Human Reproduction Update, Obstetrics and Gynecology, Reproductive Biology and Endocrinology, Reproductive Biomedicine Online og Womens Health.

Thor Haahr

- Reviewer for Frontiers in Endocrinology, Frontiers in physiology, Human Reproduction, Human Reproduction Update og Reproductive Biomedicine Online.

## Priser, legater og fondsdonationer

Birgit Alsbjerg

FER – studiet.

Gedeon Richter, 100.000 kr.

Lønmidler til study nurse funktionen.

Gedeon Richter, 500.000 kr.

IBSA, 30.000 Euro.

Merck Group, 150.000 kr.

Thor Haahr

Lundbeckfondens taletpris, 100.00 kr.